Crossmark

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Crossref DOI link: https://doi.org/10.1186/s13046-018-0702-x

Published Online: 2018-03-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Allegretti, Matteo

Fabi, Alessandra

Buglioni, Simonetta

Martayan, Aline

Conti, Laura

Pescarmona, Edoardo

Ciliberto, Gennaro

Giacomini, Patrizio https://orcid.org/0000-0001-6109-1709
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (Nuvenia Fellowship id. 19503, IG id. 14204, IG id. 19052)

Horizon 2020 Framework Programme (Grant Agreement n. 633937)
More Information

Article History

Received: 17 January 2018

Accepted: 6 February 2018

First Online: 5 March 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.